# Dime Commercial Bancshares, Inc.: financial statements, quarterly

DCOM · NYSE · CIK 846617 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/dcom.md) · [Financials](/companies/dcom/financials.md) · [Filings](/companies/dcom/filings.md) · [Insiders](/companies/dcom/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/dcom/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [4.0](/filings/0000846617-24-000063.md) | [3.8 d](/filings/0000846617-26-000013.md) | [4.5](/filings/0000846617-25-000028.md) | [4.0](/filings/0000846617-25-000040.md) | [4.3](/filings/0000846617-25-000053.md) | [3.9 d](/filings/0000846617-26-000013.md) | [4.6](/filings/0000846617-26-000030.md) | [4.6](/filings/0000846617-26-000043.md) | [5.2](/filings/0000846617-25-000053.md) | [5.4 d](/filings/0000846617-26-000013.md) | [5.7](/filings/0000846617-26-000030.md) | [6.5](/filings/0000846617-26-000043.md) |
| Interest expense | $m | [81.4](/filings/0000846617-23-000084.md) | [84.6 d](/filings/0000846617-24-000018.md) | [89.5](/filings/0000846617-24-000038.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [8.1](/filings/0000846617-24-000063.md) | [9.0 d](/filings/0000846617-26-000013.md) | [6.6](/filings/0000846617-25-000028.md) | [7.6](/filings/0000846617-25-000040.md) | [4.9](/filings/0000846617-25-000053.md) | [3.3 d](/filings/0000846617-26-000013.md) | [7.3](/filings/0000846617-26-000030.md) | [10.5](/filings/0000846617-26-000043.md) | [12.4](/filings/0000846617-25-000053.md) | [16.0 d](/filings/0000846617-26-000013.md) | [13.9](/filings/0000846617-26-000030.md) | [13.1](/filings/0000846617-26-000043.md) |
| Net income | $m | [15.0](/filings/0000846617-24-000063.md) | [16.3 d](/filings/0000846617-26-000013.md) | [17.7](/filings/0000846617-25-000053.md) | [18.5](/filings/0000846617-25-000053.md) | [13.3](/filings/0000846617-25-000053.md) | [(20.4) d](/filings/0000846617-26-000013.md) | [21.5](/filings/0000846617-26-000043.md) | [29.7](/filings/0000846617-26-000043.md) | [27.7](/filings/0000846617-25-000053.md) | [31.9 d](/filings/0000846617-26-000013.md) | [34.6](/filings/0000846617-26-000043.md) | [34.8](/filings/0000846617-26-000043.md) |
| Diluted EPS | $ per share | [0.34](/filings/0000846617-24-000063.md) | not reported | [0.41](/filings/0000846617-25-000028.md) | [0.43](/filings/0000846617-25-000040.md) | [0.29](/filings/0000846617-25-000053.md) | not reported | [0.45](/filings/0000846617-26-000030.md) | [0.64](/filings/0000846617-26-000043.md) | [0.59](/filings/0000846617-25-000053.md) | not reported | [0.75](/filings/0000846617-26-000030.md) | [0.75](/filings/0000846617-26-000043.md) |
| Basic EPS | $ per share | [0.34](/filings/0000846617-24-000063.md) | not reported | [0.41](/filings/0000846617-25-000028.md) | [0.43](/filings/0000846617-25-000040.md) | [0.29](/filings/0000846617-25-000053.md) | not reported | [0.45](/filings/0000846617-26-000030.md) | [0.64](/filings/0000846617-26-000043.md) | [0.59](/filings/0000846617-25-000053.md) | not reported | [0.75](/filings/0000846617-26-000030.md) | [0.75](/filings/0000846617-26-000043.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Total assets | $bn | [13.7](/filings/0000846617-23-000084.md) | [13.6](/filings/0000846617-25-000013.md) | [13.5](/filings/0000846617-24-000038.md) | [13.5](/filings/0000846617-24-000053.md) | [13.7](/filings/0000846617-24-000063.md) | [14.4](/filings/0000846617-26-000013.md) | [14.1](/filings/0000846617-25-000028.md) | [14.2](/filings/0000846617-25-000040.md) | [14.5](/filings/0000846617-25-000053.md) | [15.3](/filings/0000846617-26-000043.md) | [15.0](/filings/0000846617-26-000030.md) | [15.0](/filings/0000846617-26-000043.md) |
| Total liabilities | $bn | [12.4](/filings/0000846617-23-000084.md) | [12.4](/filings/0000846617-25-000013.md) | [12.3](/filings/0000846617-24-000038.md) | [12.3](/filings/0000846617-24-000053.md) | [12.5](/filings/0000846617-24-000063.md) | [13.0](/filings/0000846617-26-000013.md) | [12.7](/filings/0000846617-25-000028.md) | [12.8](/filings/0000846617-25-000040.md) | [13.1](/filings/0000846617-25-000053.md) | [13.9](/filings/0000846617-26-000043.md) | [13.5](/filings/0000846617-26-000030.md) | [13.5](/filings/0000846617-26-000043.md) |
| Shareholders' equity | $bn | [1.2](/filings/0000846617-24-000063.md) | [1.2](/filings/0000846617-26-000013.md) | [1.2](/filings/0000846617-25-000053.md) | [1.3](/filings/0000846617-25-000053.md) | [1.3](/filings/0000846617-25-000053.md) | [1.4](/filings/0000846617-26-000043.md) | [1.4](/filings/0000846617-26-000043.md) | [1.4](/filings/0000846617-26-000043.md) | [1.5](/filings/0000846617-25-000053.md) | [1.5](/filings/0000846617-26-000043.md) | [1.5](/filings/0000846617-26-000043.md) | [1.5](/filings/0000846617-26-000043.md) |

- Cash and equivalents: not reported
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [86.3 d](/filings/0000846617-24-000063.md) | [(40.0) d](/filings/0000846617-26-000013.md) | [30.7](/filings/0000846617-25-000028.md) | [12.6 d](/filings/0000846617-25-000040.md) | [(33.3) d](/filings/0000846617-25-000053.md) | [89.0 d](/filings/0000846617-26-000013.md) | [65.4](/filings/0000846617-26-000030.md) | [23.1 d](/filings/0000846617-26-000043.md) | [52.1 d](/filings/0000846617-25-000053.md) | [46.0 d](/filings/0000846617-26-000013.md) | [48.0](/filings/0000846617-26-000030.md) | [56.1 d](/filings/0000846617-26-000043.md) |
| Capital expenditure | $m | not reported | not reported | not reported | not reported | [0.8 d](/filings/0000846617-25-000053.md) | not reported | not reported | not reported | [0.9 d](/filings/0000846617-25-000053.md) | not reported | not reported | not reported |
| Dividends paid | $m | [9.5 d](/filings/0000846617-24-000063.md) | [9.3 d](/filings/0000846617-26-000013.md) | [9.5](/filings/0000846617-25-000028.md) | [9.5 d](/filings/0000846617-25-000040.md) | [9.5 d](/filings/0000846617-25-000053.md) | [9.5 d](/filings/0000846617-26-000013.md) | [10.7](/filings/0000846617-26-000030.md) | [10.7 d](/filings/0000846617-26-000043.md) | [10.7 d](/filings/0000846617-25-000053.md) | [10.8 d](/filings/0000846617-26-000013.md) | [10.8](/filings/0000846617-26-000030.md) | [10.8 d](/filings/0000846617-26-000043.md) |
| Share repurchases | $m | [0.0 d](/filings/0000846617-24-000063.md) | [0.0 d](/filings/0000846617-26-000013.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [38.2](/filings/0000846617-23-000084.md) | [38.2](/filings/0000846617-24-000038.md) | [38.2](/filings/0000846617-24-000053.md) | [38.2](/filings/0000846617-24-000063.md) | [38.3](/filings/0000846617-25-000028.md) | [38.3](/filings/0000846617-25-000040.md) | [38.4](/filings/0000846617-25-000053.md) | [42.9](/filings/0000846617-26-000030.md) | [43.0](/filings/0000846617-26-000043.md) | [43.1](/filings/0000846617-25-000053.md) | [43.1](/filings/0000846617-26-000030.md) | [43.2](/filings/0000846617-26-000043.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 44,156,595 at 2026-07-24, from the cover of the [10-Q filed 2026-07-31](/filings/0000846617-26-000043.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:25 ET. No prices; not investment advice.